Merck and Pfizer have revealed that a Phase III trial assessing avelumab in patients with gastric cancer after two prior therapeutic regimens failed to hit its primary target of showing an improvement in survival.
News
NICE issues guidelines on asthma
The National Institute for Health and Care Excellence has published new guidelines designed to improve the diagnosis and management of asthma.
AZ teams up with G1 on lung cancer combo
AstraZeneca has signed a deal with US group G1 Therapeutics to test the potential of a new combination therapy for lung cancer.
UK first to allow OTC sales of Viagra
The UK has become the first nation worldwide to allow over-the-counter sales of Pfizer’s erectile dysfunction drug Viagra.
Scotland’s pharma industry ‘a driving force’ for economic growth
New analysis highlights that Scotland’s pharmaceutical industry “can be a driving force” for long-term sustainable economic growth, says the Association of the British Pharmaceutical Industry Scotland.
Regeneron calls time on Eylea/nesvacumab combo
Regeneron says that a combination of Eylea and nesvacumab being co-developed with Bayer will not move into Phase III testing for two eye conditions following disappointing Phase II data.
NICE turns down earlier use of Eisai’s Halaven
Cost regulators for NHS treatments in England and Wales have rejected funding for Eisai’s Halaven as a second-line of attack against a certain form of breast cancer.
ViiV trials long-acting, two-drug HIV regimen
ViiV Healthcare has kicked off a late-stage study testing a long-acting, two-drug regimen of its cabotegravir and Janssen’s rilpivirine in virally suppressed adults with HIV-1 infection
AZ forms new company in China
AstraZeneca has entered into a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China.
UK Gov publishes Industrial Strategy
The government is calling two major new investments in the UK by pharma firms a “huge vote of confidence” in its approach to industrial strategy.
GSK to use Owlstone’s breath biopsy in COPD trial
In a major boon for UK diagnostics group Owlstone Medical, GlaxoSmithKline is incorporating the firm’s Breath Biopsy platform into the clinical development programme for its novel, experimental respiratory drug danirixin.
UK trial assessing AZ’ AZD1775 in head and neck cancer
A clinical trial testing AstraZeneca’s experimental drug AZD1775, an inhibitor of the cell cycle regulating protein WEE1, in patients with head and neck cancer has now launched in the UK.
PHE says uptake of bowel cancer screening too low
Public Health England is urging all men and women over the age of 60 to get screened for bowel cancer, after fresh data show over 40 percent are not getting tested, “putting thousands unnecessarily at risk of dying”.
UK launch for Medicis Health’s Reconval creams
Specialty pharma Medicis Health has launched two new products in the UK approved for relief and protection against possible serious skin problems in patients receiving treatment for cancer and multiple sclerosis.
PharmaTimes Marketer & Communications Team of the Year: See the finalists and winners in action!
Photos of the PharmaTimes Marketer & Communications Team of the Year Awards are available to view now, along with a short film about the finals day.
